About: A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 13 November 2015

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2015 (fr) наукова стаття, опублікована в листопаді 2015 (uk) scientific article published on 13 November 2015 (en) artículu científicu espublizáu en payares de 2015 (ast)
publication date	wds:Q86332051-D1664A24-39A3-4FCD-9796-6686585F15B0
publication date	2015-11-13 00:00:00Z (xsd:dateTime)
cites work	wds:Q86332051-0B413967-96D5-4D22-AE28-11F6E582F9D4 wds:Q86332051-281E37D0-2992-427B-9621-C2335F785368 wds:Q86332051-39086A08-5827-4E87-8BCA-057CE3CCAE3D wds:Q86332051-3EBDDCCE-8AD0-4432-B838-81C1DFD29152 wds:Q86332051-3F226415-C13C-4549-9C56-F0C38528B710 wds:Q86332051-411627AA-F69D-424A-AD2B-BEA4634FD257 wds:Q86332051-466C5348-1177-4AC1-B118-E8D90F778205 wds:Q86332051-93195A94-B0DE-47D6-A18A-5D3AAAB12C41 wds:Q86332051-9596C100-A69A-4312-8E92-BB75C8DD5B8D wds:Q86332051-9D8DE558-F2A6-437F-80D5-45A6EF67DBDE wds:Q86332051-9E0EF65A-82BA-48AF-B59E-FB37D04939C8 wds:Q86332051-9EAEEB27-05D3-4F8D-B273-947021225B47 wds:Q86332051-B9E0FEAC-33B9-4581-8A19-6E36A204A53D wds:Q86332051-E222F888-ECE6-4BE7-B967-D1AF41FC8580
cites work	Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Patient-reported reasons for discontinuing overactive bladder medication Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. The clinical utility index as a practical multiattribute approach to drug development decisions Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach Solifenacin significantly improves all symptoms of overactive bladder syndrome Benefit-risk assessment: the use of clinical utility index The use of a clinical utility index to compare insomnia compounds: a quantitative basis for benefit-risk assessment. A multiattribute-utility-function approach to weighing the risks and benefits of pharmaceutical agents.
author name string	wds:Q86332051-5D93E9F0-C5DF-463E-BA24-3D7CFA184482 wds:Q86332051-84F66C8F-5694-49F9-9820-6C2C0C462FD8 wds:Q86332051-C22243E2-746D-4DB5-AC03-03235088875C wds:Q86332051-D7EC5B46-FFAE-4CDF-ABC8-3DE3748DD7F1 wds:Q86332051-E57A2B33-F269-45EF-82B3-EDA46EB59B16 wds:Q86332051-F27665CB-1AD1-4239-BC31-998ADDCC68E9 wds:Q86332051-F5D65BCE-AC9D-48AC-8DB6-EC9D3D0DFE86
author name string	R Martina A Ridder D Newgreen R van Maanen C Dorrepaal I de Greef-van der Sandt M Schaddelee
rdfs:label	A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder (en) A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder (nl)
skos:prefLabel	A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder (en) A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder (nl)
name	A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder (en) A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder (nl)
title	wds:Q86332051-F82A106C-9568-453F-BC45-2ABB9C3F7A6E
title	A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder (en)
page(s)	wds:Q86332051-844D91B5-62DD-4344-AC0C-57EE9A8069F2
page(s)	442-451
instance of	wds:Q86332051-710CD72D-60D0-4854-A0FF-BD4085C34BC6
instance of	scholarly article
main subject	wds:Q86332051-6F674589-2F55-4500-82E8-3F5C8661FAF1 wds:Q86332051-83D9246F-DDD6-469A-A162-E074CA05FB73
main subject	decision making decision analysis
PubMed ID	wds:Q86332051-B82217D8-179F-4222-B04E-646A6E0D7A33
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/26422298
PubMed ID	26422298
published in	wds:Q86332051-B794427C-77C6-4022-A97C-C5B7A6342235
published in	Clinical Pharmacology & Therapeutics
issue	wds:Q86332051-53BEEAF6-50AC-4DBF-A063-8E5592F63534
volume	wds:Q86332051-F2D3C6C7-967A-4874-B681-DF0441E5E452
issue	4
volume	99
DOI	wds:Q86332051-FB5D6B11-8FE7-4382-8735-489AFC189B41
DOI	http://dx.doi.org/10.1002/CPT.271
DOI	10.1002/CPT.271
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q86332051
is cites work of	Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer
is cites work of	wds:Q90043415-CC2451D4-4D11-4E3B-83A9-6791338BA168 wds:Q64056137-ADDDED03-8761-40A8-BF25-DA4DE54731B1

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software